Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective raised by Scotiabank from $78.00 to $80.00 in a research report sent to investors on Thursday,Benzinga reports. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback